Nara Shin, Ph.D.

Strategic Partnerships Manager/msl at BostonGene

Nara Shin, Ph.D., has a diverse work experience in the field of biomedical research. Nara is currently working as a Program Alliance Manager/MSL at BostonGene, a precision oncology company, where they are responsible for developing a strong network of Key Opinion Leaders and managing multi-institutional programs in various cancers. Nara has collaborated with leading cancer institutes, conducted medical writing for case reports and manuscripts, and organized large-scale discussion meetings.

Prior to their current role, Nara worked as a Postdoctoral Research Fellow at Harvard Medical School from August 2013 to February 2021. In this position, they engaged in research activities related to their field of expertise.

Nara also worked at Severance Hospital as a Researcher from September 2012 to March 2013 and as a Doctoral Researcher from September 2008 to August 2012. During their time there, they contributed to research projects and gained valuable experience in their field.

Earlier in their career, Nara worked as a Master's student researcher at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) from September 2006 to August 2008.

Nara Shin, Ph.D., holds a Doctor of Philosophy (Ph.D.) in Medical Science from Yonsei University, College of Medicine. Prior to their Ph.D., they obtained a Master's degree in Functional Genomics from the University of Science and Technology, Korea (UST). Furthermore, they completed their Bachelor's degree in Biology/Biological Sciences, General at Handong Global University.

In addition to their formal education, Nara Shin has also pursued further certifications in their field. In October 2020, they obtained certifications in "Design and Interpretation of Clinical Trials" by Johns Hopkins University and "Drug Development" by UC San Diego, both obtained through Coursera. Additionally, they obtained an MSL certificate from "from SCIENCE to PHARMA" (FSTP) through their MSL global online training program in April 2020.

Links